Bluejay Diagnostics Inc. (NASDAQ: BJDX) has completed a financial transaction with institutional investors, raising approximately $3.7 million through a warrant inducement agreement. The medical technology company secured the funds by facilitating the exercise of existing warrants at a reduced price of $3.42 per share.
Under the terms of the transaction, investors were able to purchase up to 1,085,106 shares of common stock. As part of the agreement, investors received new five-year warrants for the same number of shares, maintaining the $3.42 per share exercise price.
The financial maneuver provides Bluejay Diagnostics with additional capital to support its ongoing development of the Symphony platform, which focuses on rapid diagnostics for critical care settings. The company's primary product candidate is an IL-6 Test for sepsis, designed to deliver accurate results within approximately 20 minutes.
Aegis Capital Corp. served as the exclusive financial advisor for the transaction, with legal support provided by Hogan Lovells US LLP for the company and Kaufman & Canoles, P.C. for Aegis.
This capital infusion could potentially accelerate Bluejay Diagnostics' efforts to advance its diagnostic technologies, particularly its sepsis triage and monitoring solutions, which aim to improve patient outcomes through rapid and precise testing.
